Robert Kwun, MD
Retina Specialist · Salt Lake City, UTNPI 1457338162
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $236,542 of the $334,399 with a category attached, or 70.7%. 17 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 50.1% of the total. Reporting peaked in 2019 at $123,047 and has fallen 86.9% since, to $16,123 in 2025. Among retina specialist clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 407 payments — averaging $821.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$167K
- Genentech USA, Inc.$102K
- Novartis$37K
- Regeneron$11K
- AbbVie$9K
- Alimera Sciences, Inc.$3K
- plus $5K from 11 others
Across 390 payments — averaging $4205.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.1M
- Boehringer Ingelheim$177K
- Boehringer Ingelheim International GmbH$125K
- Janssen Research & Development, LLC$116K
- Regeneron$75K
- Astellas Pharma Global Development$36K
- plus $9K from 2 others
What the payments were for
- Consulting fees$35,48111%
- Speaking & faculty fees$236,54271%
- Travel & lodging$50,20715%
- Food & beverage$9,9843%
- Ownership interest$2,1851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 156 | $167,421 |
| Genentech USA, Inc. | 117 | $102,043 |
| Novartis | 37 | $36,866 |
| Regeneron | 20 | $11,234 |
| AbbVie(2 entities) | 30 | $8,694 |
| Alimera Sciences, Inc. | 8 | $2,675 |
| US Retina LLC | 6 | $2,185 |
| Apellis Pharmaceuticals, Inc. | 4 | $934 |
| BD | 1 | $900 |
| Eyepoint US, Inc. | 13 | $594 |
| Astellas Pharma US Inc | 6 | $248 |
| Astellas Pharma Global Development | 1 | $160 |
| Cardinal Health 110 LLC | 1 | $150 |
| Biogen | 2 | $88 |
| Genentech, Inc. | 3 | $79 |
| Amgen | 1 | $74 |
| Glaukos Corporation | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$334,399 in reported general payments places this provider in the 95th percentile of 20 retina specialist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 25 | $908 |
| Bromfenac Sodium | 12 | $617 |
| MoxifloxacinMoxifloxacin Hcl | 18 | $388 |
| Timolol Maleate | 26 | $355 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Salt Lake City
- Mitchell GoffSalt Lake City$165K
- James HowardSalt Lake City$14K
- David FaberSalt Lake City$10K
- Rebekah GensureSalt Lake City$5K
- Kirk WinwardSalt Lake City$3K
- Eric BrintonSalt Lake City$3K
- Gregory BrintonSalt Lake City$1K
- Mano SwartzSalt Lake City$28
- Andrew DavisWest Jordan$4K
- Joshua CarlsonSt George$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.